FindMyRecallSubscribe
Class I: serious health riskTerminated

Pfizer 2% Lidocaine HCl Injection Recall

2% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT Unit of Use Syringe…

Pfizer Inc. · New York, NY

Risk level
Class I
Reported by FDA
Nov 15, 2023
Recall ID
D-0102-2024
Check your lot numberHow we source this data

Summary

Pfizer recalled 2% Lidocaine HCl Injection starting Oct 2, 2023. The FDA classified it as Class I (serious health risk) and published enforcement report D-0102-2024 on Nov 15, 2023. Reason: Presence of Particulate Matter: identified as glass. Status: Terminated.

Why it was recalled

Presence of Particulate Matter: identified as glass.

Product description

2% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Distributed by Hospira Inc., Lake Forest, IL 60045, NDC 0409-4903-11

Lot numbers, UPCs & expiration codes

Lot#: GH6567, Exp. 7/1/2024

Where it was sold

Nationwide in the US and Puerto Rico. The products were not distributed to government accounts or foreign consignees.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0102-2024
Classification
Class I
Status
Terminated
Recall initiated
Oct 2, 2023
FDA report date
Nov 15, 2023
Quantity
3,200 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Pfizer Inc.

Original FDA data

Every field from FDA enforcement report D-0102-2024, exactly as published.

Show all FDA fields
City
New York
State
NY
Status
Terminated
Country
United States
Event ID
93124
Address
235 East 42nd Street
Code information
Lot#: GH6567, Exp. 7/1/2024
Postal code
10017-5703
Report date
Nov 15, 2023
Product type
Drugs
Recall number
D-0102-2024
Classification
Class I
Recalling firm
Pfizer Inc.
Product quantity
3,200 vials
Termination date
Feb 14, 2025
Reason for recall
Presence of Particulate Matter: identified as glass.
Voluntary / mandated
Voluntary: Firm initiated
Product description
2% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Distributed by Hospira Inc., Lake Forest, IL 60045, NDC 0409-4903-11
Distribution pattern
Nationwide in the US and Puerto Rico. The products were not distributed to government accounts or foreign consignees.
Recall initiation date
Oct 2, 2023
Initial firm notification
Letter
Center classification date
Nov 9, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0102-2024, published Nov 15, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls